Valziflocept
Based on 1 Customer Validation
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.00%
- CAS. Nr.: 1804910-11-9
- Molecular Weight:19.693 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Valziflocept significantly inhibits phagocytosis of IgG-opsonised murine red blood cells by thioglycolate-elicited peritoneal macrophages from female NZB/NZW F1 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Valziflocept (50-150 μg/week; s.c.; weekly; 4 weeks) delays onset of lupus pathology and improves survival in NZB/NZW F1 mice, while valziflocept (100 μg/week; s.c.; weekly; until death or study end (therapeutic)) significantly prolongs survival despite established kidney damage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1 (male, age-matched, collagen-induced arthritis model)[1]
-
Dosage:200 μg per dose
-
Administration:i.v.; 5 occasions with 3-day intervals
-
Result:Reduced mean arthritic score to 6.1 at 12 days after first treatment and 14.2.
Reduced serum IgG anti-collagen type II antibody levels significantly 2 weeks after treatment start.
Reduced TNF-α and IL-6 mRNA levels significantly in lymph nodes.
Reduced TGF-β1, TGF-β2, TGF-β3, and MIF mRNA levels in synovial tissue.
-
Animal Model:NZB/NZW F1 (female, 5-8 weeks old at study start)[2]
-
Dosage:50 μg/week; 100 μg/week; 150 μg/week
-
Administration:s.c.; weekly; 4 weeks
-
Result:Significantly delayed onset of proteinuria with 3×50 μg/week prophylactic treatment.
Prolonged survival by 11.5 weeks with 3×50 μg/week prophylactic treatment.
Delayed weight loss and delayed development of anaemia with 3×50 μg/week prophylactic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 3×50 μg/week prophylactic treatment.
Showed a non-significant trend towards prolonged survival with 1×150 μg/week prophylactic treatment.
Significantly prolonged survival with 1×100 μg/week therapeutic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 1×100 μg/week therapeutic treatment.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FCGR2B (immunoglobulin G Fc receptor low affinity IIb, Fc gamma RIIb, CD32, CD32b)
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 1804910-11-9
-
Appearance Liquid
-
Molecular Weight 19.693 kDa
-
Color Colorless to light yellow
-
SMILES
[Valziflocept]
-
Synonyms
BAX1810; TAK-752; SM101
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Magnusson SE, et al. Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. Clin Immunol. 2008;127(2):225-233. [Content Brief]
[2]. Werwitzke S, et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis. 2008 Feb;67(2):154-61. [Content Brief]
[3]. Zuercher AW, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Valziflocept Related Classifications
HY-P99529 Related Classifications
Powered by Bioz
- Valziflocept
- 1804910-11-9
- BAX1810
- TAK-752
- SM101
- BAX 1810
- BAX-1810
- TAK752
- TAK 752
- TAK-752
- SM101
- SM 101
- SM-101
- Fc Receptor (FcR)
- macrophages
- inflammatory cytokines
- murine erythrocytes
- IgG anti-collagen type II antibodies
- NZB/NZW F1 mice
- mouse IgG
- Fcγ receptor
- collagen-induced arthritis
- systemic lupus erythematosus
- immune complexes
- Inhibitor
- inhibitor
- inhibit